Skip to main content

Table 2 Monoclonal antibodies for relapsing-remitting multiple sclerosis (RRMS)

From: Recent developments in multiple sclerosis therapeutics

Agent Proposed mechanisms of action Stage of development*
Alemtuzamab Leukocyte depletion; Depletes CD52 B and T cell populations, monocytes, macrophages and eosinophils Phase III for RRMS
Daclizumab Leukocyte depletion; Binds cell-surface receptor IL2; reduces T cell proliferation and activation Phase II for RRMS
Rituximab B cell-directed therapy; Depletes CD20 B cell population Phase III for RRMS
  1. *Compiled from http://www.clinicaltrials.gov